The Journal of family practice
-
This UK study revealed the benefits of introducing gluten at age 4 months.
-
Chronic kidney disease (CKD) remains underrecognized by patients and clinicians in the primary care setting, largely due to its asymptomatic presentation in early stages. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors have demonstrated kidney-protective effects in clinical trials-including in patients with and without type 2 diabetes (T2D)-and there are several proposed mechanisms for these benefits. Dapagliflozin and canagliflozin are SGLT2 inhibitors with indications for CKD, and only dapagliflozin is indicated for CKD in patients without T2D. Clinically relevant adverse events associated with SGLT-2 inhibitors include volume depletion, diabetic ketoacidosis, and genital mycotic infections.
-
Identify patients who are good candidates for a continuous glucose monitor (CGM) vs fingerstick self-monitoring of blood glucose (SMBG) Discuss the information provided by CGM systems Generate and interpret patient CGM data using the ambulatory glucose profile (AGP) to assess time targets established by the International Consensus on Time in Range Modify the treatment plan based on CGM data to improve patient outcomes.
-
The gut microbiome, sometimes referred to as the "organ" we do not know we have, is a dynamic ecosystem that plays an important role in human health and disease. Alterations in the gut microbiome (dysbiosis) are associated with wide-ranging disease states, including metabolic diseases like type 2 diabetes mellitus (T2D). Growing evidence suggests improved gut microbiome composition from targeted microbiome interventions leads to improvement in glycemic control in patients with T2D.
-
The increasing prevalence of type 1 diabetes (T1D) suggests family physicians will regularly see first-degree relatives of patients with T1D with the genetic propensity for developing T1D. T1D autoantibody screening by family clinicians addresses an important need to identify at-risk individuals early and achieve short- and long-term health benefits. Multiple T1D screening options and programs are available to clinicians that provide patient education, testing, result analysis, follow-up, and opportunity for participation in T1D prevention trials. The provider-patient relationship in family medicine places clinicians in a unique position to provide monitoring and followup crucial to family members with positive autoantibody results.